Modification of amyloid-β1-42 fibril structure by methionine-35 oxidation

Journal of Alzheimer's Disease

Volumn 37, Issue 1, 2013, Pages 9-18

  Hou, Liming ^a   Lee, Hyoung Gon ^b   Han, Fang ^c   Tedesco, Johnathan M ^d   Perry, George ^a,e   Smith, Mark A ^b   Zagorski, Michael G ^c  

^a ABBOTT VASCULAR   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d Lake Erie College   (United States)

^e University of San Antonio   (United States)

Author keywords

Alzheimer's disease; amyloid ; atomic force microscopy; fibrillization; oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CONGO RED; METHIONINE 35; RADIOPHARMACEUTICAL AGENT; SULFOXIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; ATOMIC FORCE MICROSCOPY; BIREFRINGENCE; BRAIN; CHEMICAL STRUCTURE; ELECTRON MICROSCOPY; FIBER; HUMAN; IN VITRO STUDY; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN MODIFICATION; PROTEIN PROCESSING; SENILE PLAQUE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; HUMANS; METHIONINE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEPTIDE FRAGMENTS;

EID: 84883195841     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122389     Document Type: Article

References (86)

1. Smith MA (1998) Alzheimer disease. Int Rev Neurobiol 42, 1-54. (Pubitemid 128788937)
2. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766. (Pubitemid 32267077)
3. Shah RS, Lee HG, Xiongwei Z, Perry G, Smith MA, Castellani RJ (2008) Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother 62, 199-207. (Pubitemid 351635842)
4. Zagorski MG, Yang J, Shao H, Ma K, Zeng H, Hong A (1999) Methodological and chemical factors affecting amyloid peptide amyloidogenicity. In Amyloid, Prions, and Other Protein Aggregates,Wetzel R, ed. Academic Press, NewYork, pp. 189-204. (Pubitemid 29446450)
5. Bitan G, Teplow DB (2005) Preparation of aggregate-free, low molecular weight amyloid-for assembly and toxicity assays. Methods Mol Biol 299, 3-9.
6. Inouye H, Kirschner D (1996) Refined fibril structures: The hydrophobic core in Alzheimer's-amyloid and prion as revealed by X-ray diffraction. In The Nature and Origin of Amyloid Fibrils, Bock GR, Goode JA, eds. John Wiley & Sons, New York, NY, pp. 22-39.
7. Harper JD,Wong SS, Lieber CM, Lansbury PT (1997) Observation of metastable Aamyloid protofibrils by atomic force microscopy. Chem Biol 4, 119-125. (Pubitemid 27161750)
8. Tycko R (2006) Characterization of amyloid structures at the molecular level by solid state nuclear magnetic resonance spectroscopy. Methods Enzymol 413, 103-122. (Pubitemid 44528687)
9. Kodali R,WetzelR(2007) Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struct Biol 17, 48-57. (Pubitemid 46242190)
10. Simmons LK, May PC, Tomaselli KJ, Rydel RE, Fuson KS, Brigham EF, Wright S, Lieberburg I, Becker GW, Brems DN, Li W (1994) Secondary structure of-amyloid peptide correlates with toxicity in vitro. Mol Pharmacol 45, 373-379. (Pubitemid 24094924)
11. Yamamoto M, Kiyota T, Walsh SM, Ikezu T (2007) Kinetic analysis of aggregated amyloid-peptide clearance in adult bone-marrow-derived macrophages from APP and CCL2 transgenic mice. J Neuroimmune Pharmacol 2, 213-221.
12. Selkoe DJ (2008) Soluble oligomers of the amyloid-protein impair synaptic plasticity and behavior. Behav Brain Res 192, 106-113.
13. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A,Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT (2008) Rapid appearance and local toxicity of amyloid-plaques in amouse model of Alzheimer's disease. Nature 451, 720-724. (Pubitemid 351220570)
14. Ono K, Naiki H, Yamada M (2006) The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of-amyloid fibrils (fAr), as well as destabilize preformed fAr. Curr Pharm Des 12, 4357-4375. (Pubitemid 44718294)
15. Barten DM, Albright CF (2008) Therapeutic strategies for Alzheimer's disease. Mol Neurobiol 37, 171-186.
16. Smith MA, Sayre LM, Monnier VM, Perry G (1995) Radical AGEing in Alzhimer's disease. Trends Neurosci 18, 172-176.
17. Markesbery WR (1999) The role of oxidative stress in Alzheimer disease. Arch Neurol 56, 1449-1452.
18. Sayre LM, Smith MA, Perry G (2001) Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 8, 721-738. (Pubitemid 32427903)
19. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA (2006) Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 65, 631-641. (Pubitemid 44297254)
20. Robinson RA, Lange MB, Sultana R, Galvan V, Fombonne J, Gorostiza O, Zhang J, Warrier G, Cai J, Pierce WM, Bredesen DE, Butterfield DA (2011) Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: Effects of the amyloid-beta peptide of amyloid precursor protein (Xi). Neuroscience 177, 207-222.
21. Milton NG (2004) Role of hydrogen peroxide in the aetiology of Alzheimer's disease: Implications for treatment. Drugs Aging 21, 81-100. (Pubitemid 38294378)
22. Li F, Calingasan NY, Yu F, Mauck WM, Toidze M, Almeida CG, Takahashi RH, Carlson GA, Flint Beal M, Lin MT, Gouras GK (2004) Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J Neurochem 89, 1308-1312. (Pubitemid 38715849)
23. Levine RL, Mosoni L, Berlett BS, Stadtman ER (1996) Methionine residues as endogenous antioxidants in proteins. Proc Natl Acad Sci USA 93, 15036-15040. (Pubitemid 27009547)
24. Schoneich C (2005) Methionine oxidation by reactive oxygen species: Reaction mechanisms and relevance to Alzheimer's disease. Biochim Biophys Acta 1703, 111-119. (Pubitemid 40170434)
25. KuoYM,Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE (2001) Comparative analysis of A chemical structure and amyloid plaque morphology of transgenic mice and Alzheimer disease brains. J Biol Chem 276, 12991-12998.
26. Hou L, Kang I, Marchant RE, Zagorski MG (2002) Methionine-32 oxidation reduces fibril assembly of the amyloid A (1-42) peptide of Alzheimer's disease. J Biol Chem 277, 40173-40176. (Pubitemid 35215584)
27. Palmblad M, Westlind-Danielsson A, Bergquist J (2002) Oxidation of methionine-35 attenuates formation of amyloid-peptide 1-40 oligomers. J Biol Chem 277, 19506-19510. (Pubitemid 34967462)
28. Bitan G, Tarus B, Vollers SS, Lashuel HA, Condron MM, Straub JE, Teplow DB (2003) A molecular switch in amyloid assembly: Met35 and amyloid-protein oligomerization. J Am Chem Soc 125, 15359-15365. (Pubitemid 37532178)
29. Hou L, Shao H, Zhang Y, Li H, Menon NK, Neuhaus EB, Brewer JM, Byeon IJ, Ray DG, Vitek MP, Iwashita T, Makula RA, Przybyla AB, Zagorski MG (2004) Solution NMR studies of the A (1-40) and A (1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc 126, 1992-2005. (Pubitemid 38228879)
30. Johansson AS, Bergquist J, Volbracht C, Paivio A, Leist M, Lannfelt L, Westlind-Danielsson A (2007) Attenuated amyloid-aggregation and neurotoxicity owing to methionine oxidation. Neuroreport 18, 559-563. (Pubitemid 46594915)
31. Fezoui Y, Hartley DM, Harper JD, Khurana R, Walsh DM, Condron MM, Selkoe DJ, Lansbury PT, Jr Fink AL, Teplow DB (2000) An improved method of preparing the amyloid-protein for fibrillogenesis and neurotoxicity experiments. Amyloid 7, 166-178.
32. Watson AA, Fairlie DP, Craik DJ (1998) Solution structure of methionine-oxidized amyloid-peptide (1-40). Does oxidation affect conformational switching? Biochemistry 37, 12700-12706. (Pubitemid 28433500)
33. Hensley K,Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA (1998) Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 18, 8126-8132. (Pubitemid 28464991)
34. Yip CM, McLaurin J (2001) Amyloid-beta peptide assembly: A critical step in fibrillogenesis and membrane disruption. Biophys J 80, 1359-1371. (Pubitemid 32182160)
35. Ding TT, Harper JD (1999) Analysis of amyloid-assemblies using tapping mode atomic force microscopy under ambient conditions. In Amyloid, Prions, and Other Protein Aggregates, Wetzel R, ed. Academic Press, New York, pp. 510-525. (Pubitemid 29446470)
36. Harper JD, Wong SS, Lieber CM, Lansbury PT, Jr (1999) Assembly of Aamyloid protofibrils: An in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38, 8972-8980.
37. Kowalewski T, Holtzman DM (1999) In situ atomic force microscopy study of Alzheimer's-amyloid peptide on different substrates: New insights into mechanism of beta-sheet formation. Proc Natl Acad Sci USA 96, 3688-3693.
38. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G, Carey PR (2003) Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42, 2768-2773. (Pubitemid 36331519)
39. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL (2003) Self-assembly of A (1-42) into globular neurotoxins. Biochemistry 42, 12749-12760.
40. Arimon M, Diez-Perez I,KoganMJ, DuranyN, Giralt E, Sanz F, Fernandez-Busquets X (2005) Fine structure study of A, 1-42 fibrillogenesis with atomic force microscopy. FASEB J 19, 1344-1346. (Pubitemid 41113744)
41. Nichols MR, Moss MA, Reed DK, Hoh JH, Rosenberry TL (2005) Rapid assembly of amyloid-peptide at a liquid/liquid interface produces unstable beta-sheet fibers. Biochemistry 44, 165-173. (Pubitemid 40095718)
42. Gosal WS, Myers SL, Radford SE, Thomson NH (2006) Amyloid under the atomic force microscope. Protein Pept Lett 13, 261-270.
43. Mastrangelo IA, Ahmed M, Sato T, Liu W, Wang C, Hough P, Smith SO (2006) High-resolution atomic force microscopy of soluble Ar42 oligomers. J Mol Biol 358, 106-119.
44. Harper JD, Lieber CM, Lansbury PT, Jr (1997) Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem Biol 4, 951-959. (Pubitemid 28050379)
45. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM,Lomakin A, Benedek GB, Selkoe DJ, TeplowDB(1999) amyloid-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274, 25945-25952.
46. Ionescu-Zanetti C, Khurana R, Gillespie JR, Petrick JS, Trabachino LC, Minert LJ, Carter SA, Fink AL (1999) Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy. Proc Natl Acad Sci USA96, 13175-13179.
47. Wetzel R (2006) Kinetics and thermodynamics of amyloid fibril assembly. Acc Chem Res 39, 671-679.
48. Stine WB, Jr., Dahlgren KN, Krafft GK, LaDu MJ (2003) In vitro characterization of conditions for amyloid-peptide oligomerization and fibrillogenesis. J Biol Chem 278, 11612-11622. (Pubitemid 36792723)
49. Stine WB, Snyder SW, Ladror UL, Wade WS, Stewart K, Miller MF, Perun TJ, Holzman TF, Krafft GA (1996) The nanometer-scale structure of amyloid-visualized by atomic force microscopy. J Protein Chem 15, 193-203. (Pubitemid 3040251)
50. Bohrmann B, Adrian M, Dubochet J, Kuner P, Muller F, Huber W, Nordstedt C, Dobeli H (2000) Self-assembly of-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates. J Struct Biol 130, 232-246.
51. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ (1995) Aggregation of secreted amyloid-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 270, 9564-9570.
52. Walsh D, Bertrand T, Kimberly W (2000) Detection of intraneuronal oligomers of the amyloid-protein. Neurobiol Aging 21, S49.
53. Kirschner DA, Abraham C, Selkoe DJ (1986) X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer's disease indicates cross-conformation. Proc Natl Acad Sci USA 83, 503-507. (Pubitemid 16080042)
54. Paravastu AK, Qahwash I, Leapman RD, Meredith SC, Tycko R (2009) Seeded growth of-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci USA 106, 7443-7448.
55. Maleknia SD, Reixach N, Buxbaum JN (2006) Oxidation inhibits amyloid fibril formation of transthyretin. FEBS J 273, 5400-5406. (Pubitemid 44772396)
56. Uversky VN, Yamin G, Souillac PO, Goers J, Glaser CB, Fink AL (2002) Methionine oxidation inhibits fibrillation of human-synuclein in vitro. FEBS Lett 517, 239-244. (Pubitemid 34327667)
57. Breydo L, Bocharova OV, Makarava N, Salnikov VV, Anderson M, Baskakov IV (2005) Methionine oxidation interferes with conversion of the prion protein into the fibrillar proteinase k-resistant conformation. Biochemistry 44, 15534-15543. (Pubitemid 41706137)
58. Binger KJ, Griffin MD, Howlett GJ (2008) Methionine oxidation inhibits assembly and promotes disassembly of apolipoprotein C-II amyloid fibrils. Biochemistry 47, 10208-10217.
59. Wetzel R, Shivaprasad S, Williams AD (2007) Plasticity of amyloid fibrils. Biochemistry 46, 1-10. (Pubitemid 46075018)
60. Esler WP, Stimson ER, Ghilardi JR, Lu Y-A, Felix AM, Vinters HV, Mantyh PW, Lee JP, Maggio JE (1996) Point substitution in the central hydrophobic cluster of a human-amyloid congener disrupts peptide folding and abolishes plaque competence. Biochemistry 35, 13914-13921.
61. Bernstein SL, Wyttenbach T, Baumketner A, Shea JE, Bitan G, Teplow DB, Bowers MT (2005) Amyloid beta-protein: Monomer structure and early aggregation states of Ar42 and its Pro19 alloform. J Am Chem Soc 127, 2075-2084. (Pubitemid 40270509)
62. Triguero L, Singh R, Prabhakar R (2008) Comparative molecular dynamics studies of wild-type and oxidized forms of full-length Alzheimer amyloid beta-peptides A (1-40) and A (1-42). J Phys Chem B 112, 7123-7131.
63. Hoyer W, Gronwall C, Jonsson A, Stahl S, Hard T (2008) Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-peptide inhibits amyloid formation. Proc Natl Acad Sci USA 105, 5099-5104. (Pubitemid 351738516)
64. Yu L, Edalji R, Harlan JE, Holzman TF, Lopez AP, Labkovsky B, Hillen H, Barghorn S, Ebert U, Richardson PL, Miesbauer L, Solomon L, Bartley D,Walter K, Johnson RW, Hajduk PJ, Olejniczak ET (2009) Structural characterization of a soluble amyloid-peptide oligomer. Biochemistry 48, 1870-1877.
65. Petkova AT, Yau WM, Tycko R (2006) Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. Biochemistry 45, 498-512. (Pubitemid 43100415)
66. Paravastu AK, Leapman RD, Yau WM, Tycko R (2008) Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. Proc Natl Acad Sci USA 105, 18349-18354.
67. Kim YS, Liu L, Axelsen PH, Hochstrasser RM (2008) Twodimensional infrared spectra of isotopically diluted amyloid fibrils from Af;40. Proc Natl Acad Sci USA 105, 7720-7725. (Pubitemid 351872705)
68. Zheng J, Jang H, Ma B, Tsai CJ, Nussinov R (2007) Modeling the Alzheimer A, 17-42 fibril architecture: Tight intermolecular sheet-sheet association and intramolecular hydrated cavities. Biophys J 93, 3046-3057. (Pubitemid 350103369)
69. Seilheimer B, Bohrmann B, Bondolfi L, Muller F, Stuber D, Dobeli H (1997) The toxicity of the Alzheimer's-amyloid peptide correlates with a distinct fiber morphology. J Struct Biol 119, 59-71. (Pubitemid 27294721)
70. Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield DA (2001) Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A (1-42) and A, (25-35). J Am Chem Soc 123, 5625-5631. (Pubitemid 32904694)
71. Clementi ME, Pezzotti M, Orsini F, Sampaolese B, Mezzogori D, Grassi C, Giardina B, Misiti F (2006) Alzheimer's amyloid-peptide (1-42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: An intriguing role for methionine 35. Biochem Biophys Res Commun 342, 206-213. (Pubitemid 43247378)
72. Maiti P, Lomakin A, Benedek GB, Bitan G (2010) Despite its role in assembly, methionine 35 is not necessary for amyloid-protein toxicity. J Neurochem 113, 1252-1262.
73. Vogt W (1995) Oxidation of methionyl residues in proteins: Tools, targets, and reversal. Free Radic Biol Med 18, 93-105.
74. Zhu X, Moreira PI, Smith MA, Perry G (2005) Alzheimer's disease: An intracellular movement disorder?. Trends Mol Med 11, 391-393. (Pubitemid 41254040)
75. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H,Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767. (Pubitemid 32678256)
76. Nunomura A, Perry G, Pappolla M, Wade R, Hirai K, Chiba S, Smith M (1999) RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 19, 1959-1964. (Pubitemid 29133374)
77. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA (2003) The production of amyloid peptide is a critical requirement for the viability of central neurons. J Neurosci 23, 5531-5535. (Pubitemid 36807828)
78. SmithMA,Casadesus G, Joseph JA, PerryG(2002) Amyloid-and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 33, 1194-1199. (Pubitemid 35246587)
79. Kontush A (2001) Amyloid-: An antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic Biol Med 31, 1120-1131. (Pubitemid 33000134)
80. Kontush A (2001) Alzheimer's amyloid-beta as a preventive antioxidant for brain lipoproteins. Cell Mol Neurobiol 21, 299-315. (Pubitemid 34001141)
81. Butterfield DA, Boyd-Kimball D (2005) The critical role of methionine 35 in Alzheimer's amyloid-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta 1703, 149-156. (Pubitemid 40170438)
82. KocA, GladyshevVN(2007) Methionine sulfoxide reduction and the aging process. Ann N Y Acad Sci 1100, 383-386. (Pubitemid 47092676)
83. Pal R, Oien DB, Ersen FY, Moskovitz J (2007) Elevated levels of brain-pathologies associated with neurodegenerative diseases in the methionine sulfoxide reductase A knockout mouse. Exp Brain Res 180, 765-774. (Pubitemid 46988121)
84. Gabbita SP, Aksenov MY, Lovell MA, Markesbery WR (1999) Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. J Neurochem 73, 1660-1666. (Pubitemid 29440169)
85. Foster JK, Verdile G, Bates KA, Martins RN (2008) Immunization in Alzheimer's disease: Naive hope or realistic clinical potential? Mol Psychiatry 14, 239-251.
86. Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT,Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M (2007) Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 357, 1382-1392. (Pubitemid 47535593)